{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T16:55:46Z","timestamp":1783702546679,"version":"3.55.0"},"reference-count":49,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2022,7,2]],"date-time":"2022-07-02T00:00:00Z","timestamp":1656720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Background: Immune checkpoint inhibitor (ICI)-associated hypothalamic\u2013pituitary\u2013adrenal axis disruption can lead to hypocortisolism. This is a life-threatening but difficult to diagnose condition, due to its non-specific symptoms that overlap with symptoms of malignancy. Currently, there is no consensus on how to best screen asymptomatic patients on ICI therapy for hypophysitis with serum cortisol. Methods: A retrospective chart review of patients treated with ICI in a tertiary care centre was conducted to assess the rate of screening with cortisol and whether this had an impact on diagnosis of ICI-hypophysitis in the preclinical stage. Patients were identified as having hypophysitis with an adrenocorticotropin hormone (ACTH) deficiency based on chart review of patients with cortisol values \u2264 140 nmol\/L (\u22645 mcg\/dL). We also assessed what proportion of cortisol values were drawn at the correct time for interpretation (between 6 AM and 10 AM). Results: Two hundred and sixty-five patients had 1301 cortisol levels drawn, only 40% of which were drawn correctly (between 6 and 10 AM). Twenty-two cases of hypophysitis manifesting with ACTH deficiency were identified. Eight of these patients were being screened with cortisol following treatment and were detected in the outpatient setting. The remaining 14 patients were not screened and were diagnosed when symptomatic, after an emergency room visit or hospital admission. Sixty percent of the cortisol tests were uninterpretable as they were not drawn within the appropriate time window. Conclusion: Measuring morning serum cortisol in asymptomatic patients on ICI therapy is a fast and inexpensive way to screen for hypophysitis and should become the standard of care. Random serum cortisol measurement has no clinical value. Education needs to be provided on when to correctly perform the test and how to interpret it and we provide an algorithm for this purpose. The adoption and validation of such an algorithm as part of routine practice could significantly reduce morbidity and mortality in patients, especially as ICI therapy is becoming increasingly commonplace.<\/jats:p>","DOI":"10.3390\/curroncol29070370","type":"journal-article","created":{"date-parts":[[2022,7,2]],"date-time":"2022-07-02T11:12:35Z","timestamp":1656760355000},"page":"4665-4677","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Routine Screening for Central and Primary Adrenal Insufficiency during Immune-Checkpoint Inhibitor Therapy: An Endocrinology Perspective for Oncologists"],"prefix":"10.3390","volume":"29","author":[{"given":"Irena","family":"Druce","sequence":"first","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Medicine, The Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON KIH8L6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Tawagi","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Medicine, The Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON KIH8L6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie L. V.","family":"Shaw","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Eastern Ontario Regional Laboratories Association, The Ottawa Hospital Research Institute, The Ottawa Hospital, The University of Ottawa, Ottawa, ON KIH8L6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Ibrahim","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Medicine, The Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON KIH8L6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Lochnan","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Medicine, The Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON KIH8L6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Ong","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Medicine, The Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON KIH8L6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,7,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa1603702","article-title":"PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma","volume":"374","author":"Nghiem","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical Hodgkin\u2019s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: A multicentre, multicohort, single-arm phase 2 trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1056\/NEJMoa1611299","article-title":"Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy","volume":"375","author":"Eggermont","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1805131","article-title":"PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma","volume":"379","author":"Migden","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S1470-2045(18)30139-6","article-title":"Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: A multicentre randomised phase 2 study","volume":"19","author":"Long","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"E40","DOI":"10.1503\/cmaj.180870","article-title":"Adverse events associated with immune checkpoint inhibitor treatment for cancer","volume":"191","author":"Esfahani","year":"2019","journal-title":"CMAJ"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/ijc.32132","article-title":"A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors","volume":"145","author":"Maillet","year":"2019","journal-title":"Int. J. Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1016\/S0140-6736(13)61684-0","article-title":"Adrenal insufficiency","volume":"383","author":"Charmandari","year":"2014","journal-title":"Lancet"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJM199610173351607","article-title":"Adrenal Insufficiency","volume":"335","author":"Oelkers","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1210\/jc.2015-1710","article-title":"Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline","volume":"101","author":"Bornstein","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1530\/EJE-19-0238","article-title":"Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis","volume":"181","author":"Faje","year":"2019","journal-title":"Eur. J. Endocrinol."},{"key":"ref_17","unstructured":"Aventis, S. (2022, June 06). Product Monograph: LIBTAYO (Cemiplimab). Available online: https:\/\/pdf.hres.ca\/dpd_pm\/00050602.PDF."},{"key":"ref_18","unstructured":"Merck (2022, June 06). Product Monograph: KEYTRUDA (Pembrolizumab). Available online: https:\/\/pdf.hres.ca\/dpd_pm\/00040232.PDF."},{"key":"ref_19","unstructured":"Pfizer (2022, June 06). Product Monograph: BAVENCIO (Avelumab). Available online: https:\/\/www.pfizer.ca\/sites\/default\/files\/201805\/BAVENCIO_PM_208742_4May2018_E.PDF."},{"key":"ref_20","unstructured":"Squibb, B.-M. (2022, June 06). Product Mongraph: YERVOY (Ipilimumab). Available online: https:\/\/pdf.hres.ca\/dpd_pm\/00042562.PDF."},{"key":"ref_21","unstructured":"Squibb, B.M. (2022, June 06). Product Monograph: OPDIVO (Nivolumab). Available online: https:\/\/pdf.hres.ca\/dpd_pm\/00042102.PDF."},{"key":"ref_22","unstructured":"Zeneca, A. (2022, June 06). Highlights of Prescribing Information: INFINZI (Durvalumab), Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/761069s000lbl.pdf."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EC-18-0068","article-title":"Society for endocrinology endocrine emergency guidance: Acute management of the endocrine complications of checkpoint inhibitor therapy","volume":"7","author":"Higham","year":"2018","journal-title":"Endocr. Connect."},{"key":"ref_24","first-page":"1263","article-title":"Basic ISSUES in Population Screening for Cancer","volume":"64","author":"Cole","year":"1980","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1210\/jcem-71-2-452","article-title":"Amplitude, but not Frequency, Modulation of Adrenocorticotropic Secretory BUrsts Give Rise to the Nyctohemeral Rhythm of the Corticotropic Axis in Man","volume":"71","author":"Veldhuis","year":"1990","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_26","first-page":"923","article-title":"Laboratory Assessment of Adrenal Insufficiency","volume":"79","author":"Grispoon","year":"1994","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1111\/j.1365-2265.1987.tb00780.x","article-title":"Value of Basal Plasma Cortisol Assays in the Assessment of Pituitary-Adrenal Insufficiency","volume":"26","author":"Hagg","year":"1987","journal-title":"Clin. Endocrinol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e261","DOI":"10.1515\/cclm-2014-1013","article-title":"To avoid fasting time, more risk than benefits","volume":"53","author":"Guidi","year":"2015","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis","volume":"4","author":"Barry","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ctrv.2017.06.002","article-title":"Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management","volume":"58","author":"Sznol","year":"2017","journal-title":"Cancer Treat. Rev."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1210\/jc.2012-4075","article-title":"Endocrine side effects induced by immune checkpoint inhibitors","volume":"98","author":"Corsello","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1080\/17446651.2019.1701434","article-title":"Hypophysitis induced by immune checkpoint inhibitors: A 10-year assessment","volume":"14","author":"Ippolito","year":"2019","journal-title":"Expert. Rev. Endocrinol. Metab."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ejca.2019.03.002","article-title":"Immune checkpoing inhibotors assocaited hypophysitis\u2014WHO VigiVase report analysis","volume":"113","author":"Guerrero","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/cen.13063","article-title":"Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: Clinical review","volume":"85","author":"Joshi","year":"2016","journal-title":"Clin. Endocrinol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/MED.0000000000000357","article-title":"Endocrine dysfunction following immune checkpoint inhibitor therapy","volume":"24","author":"Konda","year":"2017","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"R107","DOI":"10.1530\/EJE-19-0169","article-title":"Management of endocrine disease: Immune check point inhibitors-induced hypophysitis","volume":"181","author":"Albarel","year":"2019","journal-title":"Eur. J. Endocrinol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1530\/EJE-17-0810","article-title":"The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma","volume":"178","author":"Scott","year":"2018","journal-title":"Eur. J. Endocrinol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3669","DOI":"10.1007\/s00262-021-02955-y","article-title":"Mechanistic insights into immune checkpoint inhibitor-related hypophysitis: A form of paraneoplastic syndrome","volume":"70","author":"Kanie","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1210\/jc.2017-01928","article-title":"Primary Adrenal Insufficiency: Managing Mineralocorticoid Replacement Therapy","volume":"103","author":"Esposito","year":"2018","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1210\/jc.2014-2306","article-title":"Ipilimumab-induced hypophysitis: A detailed longitudinal analysis in a large cohort of patients with metastatic melanoma","volume":"99","author":"Faje","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s11102-017-0852-4","article-title":"A case series of atypical features of patients with biopsy-proven isolated IgG4-related hypophysitis and normal serum IgG4 levels","volume":"21","author":"Yuen","year":"2018","journal-title":"Pituitary"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1002\/cncr.31200","article-title":"Endocrine dysfunction induced by immune checkpoint inhibitors: Practical recommendations for diagnosis and clinical management","volume":"124","author":"Ott","year":"2018","journal-title":"Cancer"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.ando.2018.07.008","article-title":"Expert opinion on pituitary complications in immunotherapy","volume":"79","author":"Briet","year":"2018","journal-title":"Ann. Endocrinol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.ando.2018.07.005","article-title":"Endocrine side-effects of new anticancer therapies: Overall monitoring and conclusions","volume":"79","author":"Castinetti","year":"2018","journal-title":"Ann. Endocrinol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/ERC-18-0320","article-title":"French Endocrine Society Guidance on endocrine side effects of immunotherapy","volume":"26","author":"Castinetti","year":"2019","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/annonc\/mdv623","article-title":"Management of immune checkpoint blockade dysimmune toxicities: A collaborative position paper","volume":"27","author":"Champiat","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1002\/cam4.1145","article-title":"Endocrine toxicity of immune checkpoint inhibitors: Essential crosstalk between endocrinologists and oncologists","volume":"6","author":"Illouz","year":"2017","journal-title":"Cancer Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/MED.0000000000000652","article-title":"Hypophysitis from immune checkpoint inhibitors: Challenges in diagnosis and management","volume":"28","author":"Kotwal","year":"2021","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1530\/ERC-20-0513","article-title":"Immune checkpoint inhibitor related hypophysitis: Diagnostic criteria and recovery patterns","volume":"28","author":"Nguyen","year":"2021","journal-title":"Endocr. Relat. Cancer"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/29\/7\/370\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:42:10Z","timestamp":1760139730000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/29\/7\/370"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,2]]},"references-count":49,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,7]]}},"alternative-id":["curroncol29070370"],"URL":"https:\/\/doi.org\/10.3390\/curroncol29070370","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,2]]}}}